"Designing Growth Strategies is in our DNA"

Ophthalmology Biosimilars Market Size, Share & Industry Analysis, By Drug Type (Adalimumab, Aflibercept, Ranibizumab, Others), By Indication (Macular Degeneration, Diabetic Macular Edema, Retinal Detachment, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Store, Online Pharmacies) and Regional Forecast, 2024-2032

Region :Global | Report ID: FBI103109 | Status : Ongoing



Biosimilars are defined as the molecules that are similar to the existing innovator biologics. The biosimilars are also defined as the legally approved versions of the biopharmaceutical products manufactured by different sponsors having patents of the innovator product. Furthermore, these are biological products that have no clinical difference between the FDA approved biologics. Additionally, biosimilars should demonstrate similar pharmacodynamics, pharmacokinetics, and immunogenicity by focusing on the efficacy and safety of the innovator biologic to create similarity among them. In addition to this, the process of approval of biosimilar permits the submission of biological license application for interchangeable biological. This entire process requires biosimilar applicant to prove that are no difference in purity, safety, and others when compared with the branded product which is also propelling the market growth during the forecast period.

The ophthalmology biosimilars market is expected to witness robust growth during the forecast period. The major factors that are positively influencing the growth of the market are the rise in prevalence of ophthalmic diseases, growth in the recurrence of retinal diseases, rise in the geriatric population, rise in cases of diabetes, and others. According to studies, it is noted that between the age of 45-85 years the global prevalence of age-related macular degeneration was early age-related macular degeneration is projected to be 8.7% and late age macular degeneration is 0.4%. Furthermore, increase in drug discovery, improvised drug delivery for better healthcare outcomes, rise in adoption of the biosimilars by the healthcare professionals for improved patient treatment, and others are immensely boosting the growth of the market during the forecast period. Moreover, increase in research and development activities for enhancing the pipeline of the drug depending on the market trends, various initiatives conducted by government and other healthcare organizations for spreading the awareness oriented to ophthalmic diseases and for the utilization of biosimilars in treatment are expected prominently propagate the market growth in the upcoming years.

Key Market Driver -

Increasing prevalence of ophthalmological disorders

Key Market Restraint -

High cost of the treatment and patent expiration of the biologics

However, owing to drug delivery advancements in the pharmaceutical and biotechnological fields rise in drug cost and the treatment is expected to hamper the growth owing to concerns associated with patient’s access for the continuation of the therapies. Additionally, the patent's expiration for blockbuster biologics has negatively affected the production of the biologics impeding the growth of the market in the near future.

Market Segmentation:

Globally, the ophthalmology biosimilars market is segmented on bases of drug type, indication, distribution channel, and region. Based on drug type, the market is segmented into Adalimumab, Aflibercept, Ranibizumab, and others. Based on the indication, the market is segmented into macular degeneration, diabetic macular edema, retinal detachment, and others. Based on the distribution channel, the market is classified into hospital pharmacies, retail pharmacies & drug stores, online pharmacies, and others.

Geographically, the ophthalmology biosimilars market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.

Key Players Covered:

The major companies covered in the global ophthalmology biosimilars market report include Zydus Cadila, Biocon, Formycon AG, Xbrane Biopharma, Pfenex Inc., Coherus BioSciences, Biocad, Allergen, mAbxience, Intas Pharmaceuticals Ltd, and others.

Key Insights:

  • Prevalence of ophthalmic Diseases for Key Countries

  • Reimbursement Scenario for Key Countries

  • Key Mergers and Acquisitions

  • New Product Launches

  • Pipeline Analysis of Ophthalmology Biosimilars

Regional Analysis:

The global Ophthalmology Biosimilars market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the market owing to rise in ophthalmic diseases, rise in diabetic patients, increase in research and development conducted by manufactures that are focusing on the pipeline analysis of ophthalmology biosimilars, and others. Furthermore, Europe and Asia Pacific are anticipated to project significant growth in the market rise in geriatric population, increased cases of diabetics, increased healthcare expenditure, rise in healthcare awareness created by government by enhancing better healthcare delivery, owing to collaboration, mergers, and others between the major key players. For instance, prevalence of eye disease in Western China is noted to be among 3,469 children refractive error is accounted to be 20.69%, conjunctivitis is 11.76%, color vision defect is accounted to be 0.52%, macular degeneration is calculated to be 0.03%, and others.  Latin America and Middle East and Africa are expected to experience nascent growth owing to low healthcare awareness and expenditure, and others.

To gain extensive insights into the market, Request for Customization




By Drug Type

  • Adalimumab

  • Aflibercept

  • Ranibizumab

  • Others

By Indication

  • Macular Degeneration

  • Diabetic Macular Edema

  • Retinal Detachment

  • Others

By Distribution Channel

  • Hospital Pharmacies

  • Retail Pharmacies & Drug Store

  • Online Pharmacies


By Geography

  • North America (USA and Canada)

  • Europe (UK, Germany, France, Italy, Spain, Scandinavia and Rest of Europe)

  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)

  • Latin America (Brazil, Mexico and Rest of Latin America)

  • Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)

Ophthalmology Biosimilars Industry Developments

  • In July 2019, Regeneron’s new launches and pipeline is expected to emerge as outweigh for eylea biosimilar competition which is going to be collaborative project with Sanofi and Bayer AG.

  • In June 2015, Intas Pharmaceuticals Ltd launched Razumab which is the first biosimilar to Lucentis which is used for treating degenerative condition of eye.


  • Ongoing
  • 2023
  • 2019-2022

Personalize this Research

  • Granular Research on Specified Regions or Segments
  • Companies Profiled based on User Requirement
  • Broader Insights Pertaining to a Specific Segment or Region
  • Breaking Down Competitive Landscape as per Your Requirement
  • Other Specific Requirement on Customization
Request Customization Banner

Healthcare Clients

Siemens Healthineers

Client Testimonials

“We are quite happy with the methodology you outlined. We really appreciate the time your team has spent on this project, and the efforts of your team to answer our questions.”

- One of the largest & renowned medical research centers based in the U.S. on a report on the U.S. NIPT Market.

“Thanks a million. The report looks great!”

- Feedback from a consultant on a report on the U.S. Beef Market.

“Thanks for the excellent report and the insights regarding the lactose market.”

- Brazil based company specializing in production of protein ingredients.

“I liked the report; would it be possible to send me the PPT version as I want to use a few slides in an internal presentation that I am preparing.”

- Global Digital Services Agency on a report on the Global Luxury Goods Market.

“This report is really well done and we really appreciate it! Again, I may have questions as we dig in deeper. Thanks again for some really good work.”

- U.S.-based biotechnology company focussing on treatment of chronic pain.

“Kudos to your team. Thank you very much for your support and agility to answer our questions.”

- Europe-based provider of solutions to automate data centre operations.

“We appreciate you and your team taking out time to share the report and data file with us, and we are grateful for the flexibility provided to modify the document as per request. This does help us in our business decision making. We would be pleased to work with you again, and hope to continue our business relationship long into the future.”

- India-based manufacturer of industrial and specialty intermediates with a strong global presence.

“I want to first congratulate you on the great work done on the Medical Platforms project. Thank you so much for all your efforts.”

- One of the largest cosmetics company in the world.

“Thank you very much. I really appreciate the work your team has done. I feel very comfortable recommending your services to some of the other startups that I’m working with, and will likely establish a good long partnership with you.”

- U.S. based startup operating in the cultivated meat market.

“We received the below report on the U.S. market from you. We were very satisfied with the report.”

- Global hearing aids manufacturer.

“I just finished my first pass-through of the report. Great work! Thank you!”

- U.S. based solar racking solutions provider.

“Thanks again for the great work on our last partnership. We are ramping up a new project to understand the imaging and imaging service and distribution market in the U.S.”

- World’s leading advisory firm.

“We feel positive about the results. Based on the presented results, we will do strategic review of this new information and might commission a detailed study on some of the modules included in the report after end of the year. Overall we are very satisfied and please pass on the praise to the team. Thank you for the co-operation!”

- Germany based machine construction company.

“Thank you very much for the very good report. I have another requirement on cutting tools, paper crafts and decorative items.”

- Japanese manufacturing company of stationery products.

“We are happy with the professionalism of your in-house research team as well as the quality of your research reports. Looking forward to work together on similar projects”

- One of the Leading Food Companies in Germany

“We appreciate the teamwork and efficiency for such an exhaustive and comprehensive report. The data offered to us was exactly what we were looking for. Thank you!”

- Intuitive Surgical

“I recommend Fortune Business Insights for their honesty and flexibility. Not only that they were very responsive and dealt with all my questions very quickly but they also responded honestly and flexibly to the detailed requests from us in preparing the research report. We value them as a research company worthy of building long-term relationships.”

- Major Food Company in Japan

“Well done Fortune Business Insights! The report covered all the points and was very detailed. Looking forward to work together in the future”

- Ziering Medical

“It has been a delightful experience working with you guys. Thank you Fortune Business Insights for your efforts and prompt response”

- Major Manufacturer of Precision Machine Parts in India

“I had a great experience working with Fortune Business Insights. The report was very accurate and as per my requirements. Very satisfied with the overall report as it has helped me to build strategies for my business”

- Hewlett-Packard

“This is regarding the recent report I bought from Fortune Business insights. Remarkable job and great efforts by your research team. I would also like to thank the back end team for offering a continuous support and stitching together a report that is so comprehensive and exhaustive”

- Global Management Consulting Firm

“Please pass on our sincere thanks to the whole team at Fortune Business Insights. This is a very good piece of work and will be very helpful to us going forward. We know where we will be getting business intelligence from in the future.”

- UK-based Start-up in the Medical Devices Sector

“Thank you for sending the market report and data. It looks quite comprehensive and the data is exactly what I was looking for. I appreciate the timeliness and responsiveness of you and your team.”

- One of the Largest Companies in the Defence Industry
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.